Μanagement of patients with hepatitis B and C before and after liver and kidney transplantation

Table 2 Safety and efficacy of the combined regimen, interferon, ribavirin and protease inhibitors to treat hepatitis C after liver transplantation

	Boceprevir (n)	Telaprevir (n)	Complete virological response	Side effects
Coilly et al[72]	18	19	58% TVR	Anemia 92%
			89% BOC	Infections 27%
				Fatal events 8%
Pungpapong et al[73]	31	35	86% TVR	Anemia 95%
			48%BOC	Infections 10%
				Renal dysfunction 76%
				Fatal events 3%
Werner et al[74]	-	9	88.80%	Anemia 75%
				Rash 33%
				Renal dysfunction 33%
Stravitz et al[75]		50	62%	Anemia 82%
				Renal failure
				Fatal events 7%
Ann Brown et al[76]	-	46	60%	Anemia 48%
				Rash 35%
				Pruritus 22%
				Renal failure 22%
				Infections 22%
				Anorectal symptoms 41%
Forns et al[77]	Sofosbuvir 115		78%	Fatal events 16%

BOC: Boceprevir; TVR: Telaprevir.